tenofovir alafenamide
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | VEMLIDY | — | 2018-07-03 – 2024-03-27 | fda.gov ↗ |
| Approved | EU (EMA) | Genvoya | — | 2015-11-19 | europa.eu ↗ |
| Approved | US (FDA) | GENVOYA | — | 2015-11-05 | fda.gov ↗ |
Trials 153 · started per year
Also used as a comparator or background therapy in 75 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07553767 Background | Mar 2026 → Dec 2034 expected | chronic hepatitis B virus infection, hepatocellular carcinoma | Ningbo No.2 Hospital | Not yet recruiting | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT05763576 Background | Apr 2023 → Dec 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT05423106 Background | Jul 2022 → Mar 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT04629976 Comparator | Jan 2021 → Sep 2022 | chronic hepatitis B virus infection | Nucorion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03186482 Comparator | Jun 2017 → Jan 2018 | HIV infectious disease | St. Stephens Clinical Research | Completed | No outcome recorded |
| Phase 1 | NCT02962739 Comparator | Mar 2016 → May 2019 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07711223 Comparator | Nov 2025 → Aug 2028 expected | HIV infectious disease | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06150014 Comparator | Dec 2023 → Dec 2025 overdue | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03577782 Background | Sep 2018 → May 2020 | HIV infectious disease | Hospitales Universitarios Virgen del Rocío | Unknown | No outcome recorded |
| Phase 227 trials | ||||||
| Phase 2 | NCT05652478 Comparator | Jul 2026 → Jan 2028 expected | cardiomyopathy hypogonadism metabolic anomalies | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT07202546 Background | Feb 2026 → Jul 2027 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 2 | NCT05719441 Background | Aug 2024 → Apr 2028 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT06566248 Comparator | Mar → Sep 2024 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05729568 Background | May 2023 → Jul 2024 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05467553 Background | Feb 2023 → Feb 2025 | hepatitis D virus infection | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05244057 Background | Aug 2022 → Jun 2024 | chronic hepatitis B virus infection | Shanghai HEP Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05275023 Background | Jun 2022 → Dec 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05458765 Comparator | Jun 2022 → Dec 2023 | — | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 2 | NCT05256823 Background | Feb 2022 → Nov 2023 | — | Lai Wei | Unknown | No outcome recorded |
| Phase 2 | NCT04891770 Background | Aug 2021 → Jan 2024 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04820686 Background | May 2021 → Mar 2023 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04585789 Background | Mar 2021 → Feb 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04667104 Background | Feb 2021 → May 2022 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04454567 Background | Nov 2020 → Apr 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04535544 Background | Sep 2020 → Oct 2023 | hepatitis D virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04439539 Background | Sep 2020 → Aug 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04097925 Background | Feb → Aug 2020 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 2 | NCT04129554 Background | Nov 2019 → Jul 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT04059198 Background | Oct 2019 → Apr 2020 | chronic hepatitis B virus infection | F-star Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03982186 Background | Aug 2019 → Mar 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT03549689 Comparator | Aug 2019 → Jul 2021 | AIDS | Philip Grant | Withdrawn | No outcome recorded |
| Phase 2 | NCT04012931 Background | Jul 2019 → Feb 2023 | HIV infectious disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03780543 Comparator | Dec 2018 → Apr 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT03615066 Background | Aug 2018 → Dec 2019 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03576066 Background | Jun 2018 → Jul 2019 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT03491553 Background | Apr 2018 → Mar 2019 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06613685 Comparator | Oct 2024 → Mar 2026 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT06544733 Comparator | Aug 2024 → Jan 2028 expected | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04742491 Background | Mar 2021 → Aug 2024 | — | HIV Prevention Trials Network | Completed | No outcome recorded |
| Phase 317 trials | ||||||
| Phase 3 | NCT07683000 Background | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07095855 Background | Aug 2025 → Jan 2028 expected | chronic hepatitis B virus infection | Shanghai Zhimeng Biopharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07075146 Comparator | May 2025 → Jun 2026 overdue | HIV infectious disease, obesity disorder | José Antonio Mata Marín | Recruiting | No outcome recorded |
| Phase 3 | NCT06630299 Comparator | Oct 2024 → Apr 2026 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05979311 Comparator | Feb 2024 → Apr 2026 overdue | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05154747 Comparator | Jun 2023 → Mar 2025 | HIV infectious disease | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT05705349 Comparator | Mar 2023 → Oct 2025 overdue | HIV infectious disease | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05378399 Background | Dec 2022 → Feb 2026 | HIV infectious disease, substance-related disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06544551 Background | Dec 2021 → Nov 2023 | chronic hepatitis B virus infection | Beijing Kawin Technology Share-Holding Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04925752 Background | Jun 2021 → Aug 2024 overdue | — | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04542070 Comparator | Nov 2020 → Jul 2022 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT04223791 Comparator | Feb 2020 → Aug 2021 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT04079452 Background | Feb → Aug 2020 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03227861 Background | Jul 2017 → Jan 2019 | — | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03122262 Comparator | Jan 2017 → Apr 2022 | HIV infectious disease | Professor Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT02486133 Comparator | Jul 2015 → May 2018 | HIV infectious disease | Technical University of Munich | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT07138144 Comparator | Jul 2025 → Feb 2026 overdue | HIV infectious disease | José Antonio Mata Marín | Recruiting | No outcome recorded |
| Phase 4 | NCT07031063 Comparator | Apr 2025 → Dec 2026 expected | HIV infectious disease, metabolic syndrome X | Mexican Social Security Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT07573943 Background | May 2024 → Dec 2026 expected | chronic hepatitis B virus infection | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT04636437 Comparator | Jul 2021 → Oct 2024 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 4 | NCT04884139 Comparator | Jul 2021 → Feb 2024 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT04249037 Comparator | Dec 2020 → Jul 2023 | HIV infectious disease | University of Colorado, Denver | Terminated | No outcome recorded |
| Phase 4 | NCT04442737 Comparator | Jul 2020 → Aug 2023 | — | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 4 | NCT04553081 Comparator | May 2020 → Jun 2026 overdue | HIV infectious disease | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT03986697 Comparator | Feb 2020 → Mar 2021 | HIV infectious disease, coronary atherosclerosis | University of Liverpool | Withdrawn | No outcome recorded |
| Phase 4 | NCT04391608 Comparator | Nov 2019 → Jul 2022 | impaired renal function disease, poisoning | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT03933384 Comparator | Aug 2019 → Dec 2027 expected | hepatitis B virus infection | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03604016 Comparator | Sep 2018 → Jul 2020 | hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT03447873 Comparator | Jun 2017 → Sep 2020 | HIV infectious disease | Hospitales Universitarios Virgen del Rocío | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06323681 Comparator | Feb 2024 → Feb 2027 expected | chronic hepatitis B virus infection | Qing XIe | Recruiting | No outcome recorded |
| — | NCT05721300 Background | Feb 2023 → Dec 2024 | chronic hepatitis B virus infection, hepatocellular carcinoma | Zhongshan Hospital (Xiamen), Fudan University | Unknown | No outcome recorded |
| — | NCT05793268 Comparator | Dec 2022 → Dec 2025 overdue | chronic hepatitis B virus infection | E-DA Hospital | Active not recruiting | No outcome recorded |
| — | NCT05490836 Background | Sep 2022 → Aug 2024 | chronic hepatitis B virus infection | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT04231565 Comparator | Jun 2020 → Jun 2024 overdue | chronic hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT03825523 Background | Jan 2018 → Aug 2025 | HIV infectious disease | Gustavo Reyes-Teran | Completed | No outcome recorded |
Press releases naming this drug 66 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-28 | Gilead Sciences | FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six gilead.com ↗ |
| 2022-11-02 | Gilead Sciences | U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients gilead.com ↗ |
| 2020-03-10 | Gilead Sciences | Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations gilead.com ↗ |
| 2019-11-06 | Gilead Sciences | Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® gilead.com ↗ |
| 2019-10-03 | Gilead Sciences | U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP) gilead.com ↗ |
| 2019-08-09 | Gilead Sciences | China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2019-08-07 | Gilead Sciences | Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™ gilead.com ↗ |
| 2019-07-23 | Gilead Sciences | Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada® gilead.com ↗ |
| 2019-04-05 | Gilead Sciences | Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis gilead.com ↗ |
| 2019-03-26 | Gilead Sciences | Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2019-03-06 | Gilead Sciences | Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women gilead.com ↗ |
| 2019-03-06 | Gilead Sciences | Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance gilead.com ↗ |
| 2019-03-06 | Gilead Sciences | Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection gilead.com ↗ |
| 2018-12-04 | Gilead Sciences | China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2018-11-18 | Gilead Sciences | China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection gilead.com ↗ |
| 2018-10-30 | Gilead Sciences | Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ |
| 2018-10-03 | Gilead Sciences | Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ |
| 2018-08-06 | Gilead Sciences | China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2018-06-25 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2018-04-27 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) gilead.com ↗ |
| 2018-03-05 | Gilead Sciences | Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine gilead.com ↗ |
| 2018-03-05 | Gilead Sciences | Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen gilead.com ↗ |
| 2018-02-07 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2017-10-20 | Gilead Sciences | Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread® gilead.com ↗ |
| 2017-10-04 | Gilead Sciences | Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens gilead.com ↗ |
| 2017-08-10 | Gilead Sciences | Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ |
| 2017-07-24 | Gilead Sciences | Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ |
| 2017-07-13 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ |
| 2017-06-12 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment gilead.com ↗ |
| 2017-05-30 | Gilead Sciences | Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies gilead.com ↗ |
| 2017-04-20 | Gilead Sciences | Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread gilead.com ↗ |
| 2017-01-11 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection gilead.com ↗ |
| 2016-12-19 | Gilead Sciences | Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Vemlidy® for Patients With Chronic Hepatitis B Virus Infection gilead.com ↗ |
| 2016-11-11 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection gilead.com ↗ |
| 2016-11-10 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection gilead.com ↗ |
| 2016-10-24 | Gilead Sciences | Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens gilead.com ↗ |
| 2016-07-21 | Gilead Sciences | Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies gilead.com ↗ |
| 2016-06-23 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV gilead.com ↗ |
| 2016-04-29 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV gilead.com ↗ |
| 2016-04-25 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV gilead.com ↗ |
| 2016-04-15 | Gilead Sciences | Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection gilead.com ↗ |
| 2016-04-04 | Gilead Sciences | U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy gilead.com ↗ |
| 2016-03-31 | Gilead Sciences | Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection gilead.com ↗ |
| 2016-03-01 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2016-02-26 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV gilead.com ↗ |
| 2016-02-25 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B gilead.com ↗ |
| 2016-01-12 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B gilead.com ↗ |
| 2016-01-05 | Gilead Sciences | Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection gilead.com ↗ |
| 2015-11-23 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2015-11-05 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2015-10-22 | Gilead Sciences | Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV gilead.com ↗ |
| 2015-09-25 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV gilead.com ↗ |
| 2015-09-02 | Gilead Sciences | Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study gilead.com ↗ |
| 2015-08-20 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment gilead.com ↗ |
| 2015-07-21 | Gilead Sciences | Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) gilead.com ↗ |
| 2015-07-01 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) gilead.com ↗ |
| 2015-05-28 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment gilead.com ↗ |
| 2015-04-07 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment gilead.com ↗ |
| 2015-02-26 | Gilead Sciences | Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) gilead.com ↗ |
| 2014-12-29 | Gilead Sciences | Gilead Announces Amended Agreements With Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment gilead.com ↗ |
| 2014-11-06 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV gilead.com ↗ |
| 2014-09-24 | Gilead Sciences | Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies gilead.com ↗ |
| 2013-09-12 | Gilead Sciences | Gilead’s Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase 2 Study gilead.com ↗ |
| 2013-03-05 | Gilead Sciences | Gilead Announces Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF) gilead.com ↗ |
| 2013-01-24 | Gilead Sciences | Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV gilead.com ↗ |
| 2012-01-24 | Gilead Sciences | Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV gilead.com ↗ |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 240 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tenofovir alafenamide | “The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing...” NCT06630286 ↗200“This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide...” NCT02707601 ↗ “The main objective of this study is to compare the mother-to-infant transmission rates of hepatitis B between pregnant women receiving treatment with tenofovir alafenamide and...” NCT06947356 ↗ “The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance...” PMID 33315694 ↗ Apr 2021 “The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how...” NCT04039217 ↗ “The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in...” NCT02836236 ↗ “The study seeks to assess the safety of and define blood and tissue benchmark concentrations of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in...” NCT05140954 ↗ “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir...” NCT05729568 ↗ “To assess patient reported treatment satisfaction and medication tolerability in virologically suppressed HIV-1 infected adults who are at least 65 years of age who switch to a...” NCT05147740 ↗ “Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV) that is converted intracellularly to the active form, resulting in higher concentrations of TFV diphosphate in...” NCT05735535 ↗ “The single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily, integrase strand transfer inhibitor-based...” PMID 30169223 ↗ Jun 2017 “Phase IV, open, multicentre, single-arm study to evaluate the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide as a first-line treatment...” NCT03693508 ↗ “Data support the use of single-tablet coformulated bictegravir (30 mg), emtricitabine (120 mg), and tenofovir alafenamide (15 mg) for treatment of HIV in children aged at least...” PMID 38621393 ↗ Apr 2024 “tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic...” NCT02836249 ↗ “Our goal was to study the impact of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on bone mineral density (BMD) in peri- and early...” PMID 36511389 ↗ Jan 2023 “Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet, will...” NCT07138144 ↗ “The Effect of Rifampicin on the Plasma Pharmacokinetics of Emtricitabine (FTC) and Tenofovir Alafenamide Fumarate (TAF) and Intracellular Tenofovir-diphosphate (TFV-DP) and...” NCT03186482 ↗ “A Phase I Randomized, Placebo-controlled, Double-blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir...” NCT06087913 ↗ “Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for...” NCT03126370 ↗ “Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved...” NCT03780543 ↗ “The primary objective of this study is to evaluate the efficacy of tenofovir alafenamide (TAF) versus placebo, each administered with the existing, failing antiretroviral (ARV) regimen.” NCT01967940 ↗ “Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF).” PMID 30038044 ↗ Sep 2018 “A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults” NCT02071082 ↗ “Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide [BIC/FTC/tenofovir alafenamide (TAF)] is effective for HIV treatment, it was evaluated for use for PEP.” PMID 34991141 ↗ May 2022 “B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements.” NCT06375304 ↗ “Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.” NCT03577782 ↗ “NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.” NCT05763576 ↗ “Adults with HIV-1 RNA viral load of less than 50 copies/mL receiving daily bictegravir, emtricitabine, and tenofovir alafenamide combination (B/F/TAF) for 24 weeks or more.” PMID 41429026 ↗ Dec 2025 “Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.” NCT02269917 ↗ “a fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)” PMID 37752816 ↗ Sep 2023 “received either doravirine (100 mg) and islatravir (0·25 mg) or bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) orally once daily.” PMID 41763226 ↗ Feb 2026 “SBRs include medicines like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+ tenofovir alafenamide (TAF)+ emtricitabine (FTC).” NCT07683000 ↗ “A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally” NCT04950530 ↗ “Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.” NCT04311957 ↗ “Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment” NCT02296853 ↗ “Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.” NCT03877536 ↗ “Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France” NCT03858478 ↗ “A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.” NCT04442737 ↗ “However, tenofovir alafenamide (TAF) has replaced TDF due to its different safety profile for HIV treatment and was recently approved as PrEP.” PMID 32265700 ↗ Mar 2020 “co-formulated once-daily bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), herein known as the bictegravir group” PMID 29925490 ↗ Jun 2018 “Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC)” NCT03227861 ↗ “Drug-drug Interaction Study Between Bictegravir/Emtricitabine/Tenofovir Alafenamide and Feminizing Hormones in Trans Women Living With HIV” NCT05663892 ↗ “A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.” NCT04530630 ↗ “This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.” NCT04416906 ↗ “Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert” NCT04454567 ↗ “BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).” NCT04542070 ↗ “Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)” NCT06000657 ↗ “Generic TAF/E/D (tenofovir alafenamide 25mg/emtricitabine 200mg/dolutegravir 50 mg), a single-tablet once daily regimen” NCT03727152 ↗ “Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg” NCT04944654 ↗ “Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg” NCT04653194 ↗ “This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide” NCT05243602 ↗ “Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food” NCT05719441 ↗ “Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks.” NCT06544551 ↗ “Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally” NCT04047420 ↗ “B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)” NCT03348163 ↗ “once-daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF; B/F/TAF) during pregnancy.” PMID 37939141 ↗ Nov 2023 “Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine” NCT03986697 ↗ “with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine (FTC) or lamivudine (3TC)” NCT04051970 ↗ “the fixed-dose combination of 200 mg emtricitabine and 25 mg tenofovir alafenamide for 48 weeks” PMID 28219610 ↗ Feb 2017 “elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily” NCT03251144 ↗ “either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]” NCT03982186 ↗ “Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens” NCT02862548 ↗ “fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)” NCT03631732 ↗ “an insert containing tenofovir alafenamide (TAF) and elvitegravir (EVG) in healthy women.” PMID 37153145 ↗ Apr 2023 “fixed-dose tablets of tenofovir alafenamide (10 mg or 25 mg) plus emtricitabine (200 mg)” PMID 29475804 ↗ Feb 2018 “tenofovir alafenamide (F/TAF) versus emtricitabine and tenofovir disoproxil fumarate” PMID 38312459 ↗ Jan 2024 “switch or stay on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, n = 45)” PMID 39226296 ↗ Feb 2025 “bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; coformulated; Biktarvy®)” NCT06630299 ↗ “bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg)” PMID 38734016 ↗ May 2024 “Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir.” NCT02556333 ↗ “Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg” NCT04884139 ↗ “elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)” NCT02276612 ↗ “Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only” NCT04925752 ↗ “along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks” NCT03615066 ↗ “Rectally Administered Tenofovir Alafenamide/Elvitegravir Inserts” NCT06274398 ↗ “bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]” NCT03825523 ↗ “bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)” PMID 40982450 ↗ Sep 2025 “Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet” NCT04079452 ↗ “Doravirine + Emtricitibine/Tenofovir alafenamide Fumerate” NCT05457530 ↗ “Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet” NCT04097925 ↗ “Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily” NCT02656511 ↗ “study drug, tenofovir alafenamide (TAF), versus placebo” NCT02932150 ↗ “Bictegravir/emtricitabine/tenofovir alafenamide” NCT03797014 ↗ “Bictegravir/Emtricitabine/Tenofovir Alafenamide” NCT05630755 ↗ “tenofovir alafenamide (25mg/tab, once per day)” NCT05793268 ↗ “Emtricitabine/Tenofovir Alafenamide (F/TAF)” NCT02016924 ↗ “Tenofovir Alafenamide 25 mg oral once daily” NCT04780204 ↗ “emtricitabine/tenofovir alafenamide (F/TAF)” NCT04994509 ↗ “Emtricitabine/Tenofovir Alafenamide (F/TAF)” NCT02285114 ↗ “ACC017+Emtricitabine/Tenofovir Alafenamide” NCT07711223 ↗ “Tenofovir alafenamide (TAF; Vemlidy®)” NCT03491553 ↗ “tenofovir alafenamide 25 mg (F/TAF)” NCT05813964 ↗ “tenofovir alafenamide/emtricitabine” NCT04295460 ↗ “tenofovir alafenamide \[TAF\]” NCT04012931 ↗ “tenofovir alafenamide (TAF)” NCT05490836 ↗ “Tenofovir alafenamide (TAF)” NCT07542951 ↗ “Tenofovir alafenamide (TAF)” NCT03576066 ↗ “tenofovir alafenamide (TAF)” NCT06337032 ↗ “Tenofovir alafenamide (TAF)” NCT04820686 ↗ “Tenofovir alafenamide” NCT07553767 ↗ |
| Known as | alafenamide tenofovir | “Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine...” NCT06602622 ↗ |
| Known as | Descovy | “one daily tablet of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) or one daily tablet of Truvada (emtricitabine 200 mg and tenofovir disoproxil...” NCT04742491 ↗6“TDF/XTC Gé or Descovy®” NCT04051970 ↗ |
| Known as | FTC/TAF | “one daily tablet of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) or one daily tablet of Truvada (emtricitabine 200 mg and tenofovir disoproxil...” NCT04742491 ↗ |
| Known as | GS-7340 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01671787 ↗ |
| Known as | GS-7340 HEMIFUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107825 ↗ |
| Known as | GS-7340-03 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107825 ↗ |
| Known as | TAF | “Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T),...” NCT02016924 ↗101“The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how...” NCT04039217 ↗ “The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in...” NCT02836236 ↗ “In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2010/VESTED study, pregnant women were randomized to initiate dolutegravir (DTG) +...” PMID 38877762 ↗ Nov 2024 “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV) that is converted intracellularly to the active form, resulting in higher concentrations of TFV diphosphate in...” NCT05735535 ↗ “tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic...” NCT02836249 ↗ “Our goal was to study the impact of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on bone mineral density (BMD) in peri- and early...” PMID 36511389 ↗ Jan 2023 “The Effect of Rifampicin on the Plasma Pharmacokinetics of Emtricitabine (FTC) and Tenofovir Alafenamide Fumarate (TAF) and Intracellular Tenofovir-diphosphate (TFV-DP) and...” NCT03186482 ↗ “Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for...” NCT03126370 ↗ “Participants will receive either darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) fixed dose combination (D/C/F/TAF FDC) or DRV/COBI FDC...” NCT02431247 ↗ “Tenofovir Alafenamide Fumarate (TAF) is a newer, more potent prodrug of tenofovir (TFV), and in combination with FTC, has recently been approved for prevention of HIV through...” PMID 34041459 ↗ May 2021 “Tenofovir alafenamide (TAF) has been shown to cause less renal complications than tenofovir disoproxil fumarate (TDF) while having the same virological efficacy against HIV and...” NCT03115736 ↗ “First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally,...” NCT06323681 ↗ “Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B...” NCT05001672 ↗ “bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or dolutegravir/lamivudine/abacavir (DTG/3TC/ABC), are associated with metabolic, renal, and cardiovascular adverse effects” NCT07138144 ↗ “Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) has been associated with improvement in markers of renal dysfunction in individual randomized trials” PMID 30932951 ↗ Jul 2019 “Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide [BIC/FTC/tenofovir alafenamide (TAF)] is effective for HIV treatment, it was evaluated for use for PEP.” PMID 34991141 ↗ May 2022 “Real-world data regarding hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients receiving tenofovir alafenamide (TAF) as an antiviral drug are limited.” PMID 37303805 ↗ May 2023 “NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.” NCT05763576 ↗ “Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.” NCT02269917 ↗ “Studies 1878 and 1844 demonstrated non-inferior efficacy of switching suppressed HIV-1-infected adults to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)” PMID 31430369 ↗ Dec 2019 “100 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long unless the patient achieves HBsAg loss.” NCT04231565 ↗ “a fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)” PMID 37752816 ↗ Sep 2023 “Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.” NCT03693508 ↗ “Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day” NCT05898841 ↗ “SBRs include medicines like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+ tenofovir alafenamide (TAF)+ emtricitabine (FTC).” NCT07683000 ↗ “Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks” NCT05182463 ↗ “pregnant women with HBV DNA of 5.3-9.0 log 10 IU/mL who received tenofovir alafenamide fumarate (TAF) from the first day of 33 gestational weeks to delivery” PMID 39382852 ↗ Oct 2024 “Peg-IFN-α-2β combined with first-line NAs (tenofovir disoproxil fumarate [TDF], tenofovir alafenamide fumarate [TAF], tenofovir amibufen fumarate [TMF])” NCT07553767 ↗ “Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment” NCT02296853 ↗ “However, tenofovir alafenamide (TAF) has replaced TDF due to its different safety profile for HIV treatment and was recently approved as PrEP.” PMID 32265700 ↗ Mar 2020 “Tenofovir alafenamide (TAF) has emerged as a safe and effective alternative to entecavir (ETV) in the management of chronic hepatitis B (CHB).” PMID 42015653 ↗ Apr 2026 “Participants will also receive background treatment with NA (either tenofovir disoproxil, tenofovir alafenamide [TAF] or entecavir [ETV]).” NCT05275023 ↗ “Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection.” NCT04939441 ↗ “Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert” NCT04454567 ↗ “Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy” NCT04619082 ↗ “BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).” NCT04542070 ↗ “Generic TAF/E/D (tenofovir alafenamide 25mg/emtricitabine 200mg/dolutegravir 50 mg), a single-tablet once daily regimen” NCT03727152 ↗ “BACKGROUND: Tenofovir alafenamide (TAF), in combination with FTC, was recently approved for PrEP in the United States.” PMID 32539288 ↗ Jul 2020 “Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks.” NCT06544551 ↗ “This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).” NCT04629976 ↗ “emtricitabine (F) and tenofovir alafenamide (TAF), both nucleoside reverse transcriptase inhibitors (NRTIs)” NCT07476339 ↗ “A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.” NCT02475135 ↗ “Darunavir (DRV), emtricitabine (FTC), and tenofovir alafenamide (TAF) in the presence of cobicistat (COBI)” NCT04236453 ↗ “Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally” NCT04047420 ↗ “100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)” NCT05457530 ↗ “once-daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF; B/F/TAF) during pregnancy.” PMID 37939141 ↗ Nov 2023 “dolutegravir (DTG) and tenofovir alafenamide (TAF), are associated with increases in blood pressure” PMID 38978403 ↗ Jul 2024 “with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine (FTC) or lamivudine (3TC)” NCT04051970 ↗ “Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)” NCT05177926 ↗ “either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]” NCT03982186 ↗ “25mg tenofovir alafenamide (TAF) one tablet orally once a day for 4 wks (Day 14 to Day 42)” NCT05652478 ↗ “Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens” NCT02862548 ↗ “an insert containing tenofovir alafenamide (TAF) and elvitegravir (EVG) in healthy women.” PMID 37153145 ↗ Apr 2023 “Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.” NCT04195074 ↗ “Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets” NCT07202546 ↗ “Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.” NCT04196998 ↗ “fixed-dose combination of emtricitabine (FTC) 200 mg + tenofovir alafenamide (TAF) 25mg” NCT05813964 ↗ “tenofovir alafenamide (F/TAF) versus emtricitabine and tenofovir disoproxil fumarate” PMID 38312459 ↗ Jan 2024 “and tenofovir alafenamide (TAF). All these drugs are effective in viral suppression” NCT04674423 ↗ “Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet” NCT04097925 ↗ “darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF; coformulated)” NCT06630299 ↗ “Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir.” NCT02556333 ↗ “Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)” NCT07031063 ↗ “Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)” NCT04853524 ↗ “dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen” NCT05993767 ↗ “along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks” NCT03615066 ↗ “Treatment will consist of TAF 25 mg daily with food for 96 weeks.” NCT03798119 ↗ “alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC)” NCT06602622 ↗ “bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]” NCT03825523 ↗ “compare it with Tenofovir alafenamide Fumarate tablets（TAF）.” NCT06122454 ↗ “tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg” NCT07349758 ↗ “Current tenofovir alafenamide (TAF)-containing ART regimen” NCT03549689 ↗ “Tenofovir alafenamide (TAF) is an oral prodrug of TFV” NCT03251144 ↗ “receive tenofovir alafenamide (TAF) 2018-2021” NCT03695029 ↗ “tenofovir alafenamide fumarate (TAF -25mg)” NCT06338826 ↗ “Tenofovir alafenamide (TAF; Vemlidy®)” NCT03491553 ↗ “Vemlidy® (Tenofovir Alafenamide; TAF)” NCT04290936 ↗ “Tenofovir alafenamide fumarate (TAF)” PMID 41328799 ↗ Apr 2026 “Tenofovir alafenamide fumarate (TAF)” NCT04059198 ↗ “Drug: Tenofovir Alafenamide (TAF)” NCT07258251 ↗ “tenofovir alafenamide \[TAF\]” NCT04012931 ↗ “Tenofovir alafenamide (TAF)” NCT03577782 ↗ “Tenofovir Alafenamide (TAF)” NCT05423106 ↗ “Tenofovir alafenamide (TAF)” NCT04070079 ↗ “Tenofovir Alafenamide (TAF)” NCT02984852 ↗ “Tenofovir alafenamide (TAF)” NCT02437110 ↗ “tenofovir alafenamide (TAF)” NCT06337032 ↗ “Tenofovir alafenamide (TAF)” NCT04667104 ↗ “Tenofovir Alafenamide (TAF)” NCT04034368 ↗ “Tenofovir alafenamide (TAF)” NCT04129554 ↗ “tenofovir alafenamide (TAF)” NCT03631732 ↗ “Tenofovir alafenamide(TAF)” NCT03356834 ↗ “Tenofovir alafenamide（TAF）” NCT07295873 ↗ |
| Known as | Tenofovir alafenamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107825 ↗ |
| Known as | Tenofovir alafenamide (TAF) | “Patients will receive Vemlidy (tenofovir alafenamide, TAF) 25mg, daily for 48 weeks” NCT04496882 ↗ |
| Known as | Tenofovir Alafenamide (TAF) - brand name: Descovy | “Tenofovir Alafenamide (TAF) - brand name: Descovy” NCT03780543 ↗ |
| Known as | tenofovir alafenamide fumarate | “Relative Bioavailability Study to Investigate a Potential Interaction Between Dolutegravir (DTG) and Tenofovir Alafenamide Fumarate/Emtricitabine (F/TAF) Administered as...” NCT05489406 ↗20“Tenofovir Alafenamide Fumarate (TAF) is a newer, more potent prodrug of tenofovir (TFV), and in combination with FTC, has recently been approved for prevention of HIV through...” PMID 34041459 ↗ May 2021 “First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally,...” NCT06323681 ↗ “100 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long unless the patient achieves HBsAg loss.” NCT04231565 ↗ “a fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)” PMID 37752816 ↗ Sep 2023 “Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks” NCT05182463 ↗ “pregnant women with HBV DNA of 5.3-9.0 log 10 IU/mL who received tenofovir alafenamide fumarate (TAF) from the first day of 33 gestational weeks to delivery” PMID 39382852 ↗ Oct 2024 “Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks” NCT05256823 ↗ “Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks.” NCT06544551 ↗ “Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg)” NCT05154747 ↗ “Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation” NCT02771054 ↗ “Tenofovir alafenamide fumarate is a newly marketed anti-hepatitis B drug” NCT04501224 ↗ “Positive control drug：Tenofovir alafenamide Fumarate tablets（25mg/d）” NCT06122454 ↗ “Tenofovir Alafenamide Fumarate, Oral administration, once a day.” NCT06707922 ↗ “Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication.” NCT06566248 ↗ “TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]” NCT04880577 ↗ “tenofovir alafenamide fumarate (TAF -25mg)” NCT06338826 ↗ “Tenofovir alafenamide fumarate” NCT07573943 ↗ |
| Known as | Tenofovir alafenamide fumarate component of biktarvy | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107825 ↗ |
| Known as | Tenofovir alafenamide fumarate component of descovy | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107825 ↗ |
| Known as | Tenofovir alafenamide fumarate component of genvoya | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107825 ↗ |
| Known as | Tenofovir alafenamide fumarate component of odefsey | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107825 ↗ |
| Known as | Tenofovir alafenamide fumarate component of symtuza | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107825 ↗ |
| Known as | Tenofovir Alafenamide Fumarate Tablets | “Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication.” NCT06566248 ↗ |
| Known as | Tenofovir Alafenamide Hemitartrate | “Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)” NCT06000657 ↗ |
| Known as | tenofovir alefenamide fumerate | “100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)” NCT05457530 ↗ |
| Known as | Vemlidy | “Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B...” NCT05001672 ↗7“Tenofovir Disoproxil Fumarate TDF/Viread, Tenovovir Alafenamide TAF/Vemlidy, Dolutegravir DTG/Tivicay, or both TAF and DTG taken together for 4 weeks.” NCT05652478 ↗ “TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]” NCT04880577 ↗ “Tenofovir alafenamide (TAF; Vemlidy®)” NCT03491553 ↗ “Vemlidy® (Tenofovir Alafenamide; TAF)” NCT04290936 ↗ |
| Known as | Vemliver | “Efficacy and Safety of Switching to Vemliver (Tenofovir Alafenamide) From Entecavir in Chronic Hepatitis B: A Multi-Center, Phase IV, Open-Label, Randomized, Active-Controlled,...” NCT06000657 ↗ |
| Action | Inhibit | “It acts as a nucleoside reverse transcriptase inhibitor.” NCT02437110 ↗ |
| Modality | Small molecule | “the antiviral nucleoside analogue, Tenofovir alafenamide (TAF)” NCT04070079 ↗ |
| Route | Oral | “Tenofovir alafenamide tablet(s) administered orally once daily” NCT00036634 ↗ |